Brownson >> it is very rare for any commercial deals for upfront payments / volumes to be revealed because it would put them ABCAM in a weak position in negotiating future deals with other partners. Also it could cause rediscussion / resentment for existing partners.
Understanding the importance of such arrangements can only come from attending Tepnel meetings where such questions can be asked (may not always be answered though).
For those who were unuaware -
Abcam is a rapidly growing business, specialising in the production and sale of antibody research reagents, with offices in Cambridge, UK, Cambridge, MA, USA and Tokyo, Japan.
Abcam's mission is to build the largest online catalog of the best antibodies in the world. Their scientists are dedicated to building a catalog of the best antibodies in the world. They make their own antibodies and source other excellent antibodies from institutes, academic laboratories and primary manufacturers. They provide technical support on all of their products to enable the customer to achieve the result they would expect. Abcam was founded in 1998 out of the University of Cambridge. More info on ABCAM can be found at their web site - www.abcam.com.
I see this as very good news because Diaclone has many excellent immunological products but they need the distribution channel to maximise the potential. This agreement will certainly help achieve that goal.
Tepnel Life stock quotes
Tepnel Life stock charts
Follow this thread
